Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /PRNewswire/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people ...

Panelists discuss the emotional and diagnostic journey of a multiple myeloma patient and his care partner, highlighting how ...

Creative Biolabs has a professional platform that provides customized CAR construction and design, meeting diverse needs of CAR-T cell therapy resear ...

Regular physical activity lowers cancer risk, aids recovery and improves survival. In this expert-led interview, we explore ...

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

Lynozyfic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

Researchers have identified ways in which chemotherapy can damage healthy cells and found that some drugs can add decades of ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of ...